Isomorphic Labs raises $5 billion Series C co-led by Greenoaks and Sequoia
Isomorphic Labs, the London AI drug discovery company that spun out of Google DeepMind in 2021, has raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital. C&EN reported it on 18 November from the company’s press release; Alternatives Watch puts its venture funding at $7.7 billion across three rounds.
Who put money into Isomorphic Labs’ Series C?
Greenoaks and Sequoia Capital led, Andreessen Horowitz joined as a new investor, and Alphabet, Isomorphic’s main owner, put in more, according to C&EN. MobiHealthNews adds that all existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.
The money follows a $2.1 billion Series B earlier in 2026, C&EN notes. MobiHealthNews places the first external round, $600 million led by Thrive Capital, in the year before.
The company says the funds will “mature” its drug design platform, the Isomorphic Labs Drug Design Engine (IsoDDE), launched in February. By the company’s account, IsoDDE beats AlphaFold 3 at predicting protein-ligand structures and, unlike AlphaFold 3, covers small-molecule binding affinities too. Since then it has added AI agents of its own that reason. “Our drug design engine is generating molecules with unprecedented precision and speed,” Demis Hassabis says in the release, as C&EN quotes it.
What does Ins7ghts’ record of Isomorphic Labs show?
A company read mostly next to its own family, with its loudest weeks in summer rather than this one. In the news Ins7ghts collected from 13 July to 20 November 2026, 161 articles named Isomorphic Labs. The busiest weeks were 3 to 9 August, with 36 articles, and 27 July to 2 August, with 25. None of the sources linked here says what drew that attention.
When the record picks out other companies in those articles, it’s mostly Isomorphic’s own family, so Google DeepMind, Alphabet and Google, plus Anthropic and OpenAI. I went looking for Greenoaks and Sequoia, the two investors leading this round, and they’re not in there yet.
One earlier event in the record shows the same company described two ways. On 7 October News-Medical carried the announcement that Google DeepMind, Isomorphic Labs and Meta are collectively investing $300 million in the Virtual Biology Initiative, part of a $1.8 billion effort with Biohub, the US Department of Energy and the National Institutes of Health. Max Jaderberg, President of Isomorphic Labs, put it as data work: “By joining the Virtual Biology Initiative as a founding member, Isomorphic Labs is helping build a massive, multimodal data foundation.” On 10 October Benzinga’s roundup filed the same money under Meta, as “a Mark Zuckerberg-backed effort to build AI models that can predict how living cells behave.”
What should buyers of AI drug discovery tools watch next?
The first human trials. The round is meant to carry Isomorphic’s first drug candidates into clinical trials, and none of these sources gives a date for that step.
Until then the evidence is the company’s own: “positive preclinical results” in its oncology and immunology programs and in work with Eli Lilly and Company, Novartis and Johnson & Johnson, as C&EN reports it. C&EN also sets the bar, nearly a decade and close to $2 billion to take a molecule through clinical trials. “I think it is uncontroversial that they are going to have to show that they can do it faster, better, and cheaper, and they are going to have to show that pretty soon,” Jack Scannell, founder of Etheros Pharmaceuticals, told C&EN.
For a pharma team weighing an AI design partner, that is the question to bring to any such deal: which molecules from the engine have reached a trial, and when.
Isomorphic Labs’ full record in Ins7ghts holds every dated event with the article it came from: ins7ghts.com, or the Ins7ghts newsletter each morning.
Small print. The counts describe the news Ins7ghts collected from 13 July to 20 November 2026, not all news about Isomorphic Labs. AI models read the articles and listed the companies and events in them. Two articles were used for facts but not linked, because their pages refuse readers today: MobiHealthNews on the round and Benzinga’s 10 October roundup; their text comes from our archive. Dates are the articles’ publication dates. AI models read the articles, wrote this take and checked every quote against its source on 20 November. I see each take the evening before it goes out.


